Menu

Prescribing guidelines

Loading…

Clinical support by body system

Conditions and indicators

Alcohol dependence1
Allergic rhinitis1
Angina pectoris1
Antiplatelets1
Asthma2
Atrial fibrillation1
Cancer : Palliative care2
Depression2
Dysphagia1
Epilepsy2
Heart failure4
Incontinence2
Inflammatory Bowel Disease1
Neuropathic pain1
Obesity and bariatric surgery1
Osteoporosis2
Pain management9
Peptic ulcers1
Rheumatoid arthritis1
Stroke2
Substance dependence1
Transient Ischaemic Attack TIA1
Type 1 Diabetes2
Type 2 Diabetes2

Traffic light

April 2022 - APC Approved list of guideline review date extensions (to 3 years from date approved)

1
2
3
4
5
6
7
8
9
10
Next
Last

CVS: Furosemide (frusemide)- Guidance for prescribing Subcutaneous Furosemide

Cardiovascular and Lipids

Guidance for the assessment and treatment of end stage heart failure by subcutaneous furosemide for the treatment of symptomatic fluid overload
CVS: Heart Failure Pathway (APC Approved)
CVS: Hypertension - antihypertensive medication (APC approved)

Cardiovascular and Lipids Endocrine and Diabetes
CVS: NOAC- management of bleeding

Cardiovascular and Lipids Laboratory investigations and Infections
CVS: NOACS - newer oral anticoagulants

Cardiovascular and Lipids Laboratory investigations and Infections
CVS: Optimising Lipid Management for Secondary Prevention of Cardiovascular Disease in Barnsley (APC Approved)
CVS: Spironolactone - Position Statement on MHRA Drug Safety Update

Cardiovascular and Lipids
CVS: Switching Between Oral Anticoagulants

Cardiovascular and Lipids
CVS: Ticagrelor guidelines

Cardiovascular and Lipids
Dandruff Position Statement (APC Approved)

1
2
3
4
5
6
7
8
9
10
Next
Last

Did you find this page helpful?